Author:
Kwok Charlotte S.,Johnson Emily L.,Krauss Gregory L.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology
Reference70 articles.
1. US Food and Drug Administration. Step 3: clinical research. US Food Drug Administration. [Internet]. 2015; pp 1–4. http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm#Clinical_Research_Phase_Studies . Accessed 9 Aug 2017.
2. Rosenfeld W, Fountain NB, Kaubrys G, Ben-Menachem E, Mcshea C, Isojarvi J, et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav. 2014;41:164–70. https://doi.org/10.1016/j.yebeh.2014.09.074 .
3. Edwards HB, Cole AG, Griffiths AS, Lin B, Bean A, Krauss GL. Minimizing pharmacodynamic interactions of high doses of lacosamide. Acta Neurol Scand. 2012;125:228–33.
4. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J. 1997;314:180–1.
5. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology [Internet]. 1998;50:614–8. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=9521245&site=ehost-live . Accessed 9 Aug 2017.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献